enpatoran   Click here for help

GtoPdb Ligand ID: 11307

Synonyms: compound 73 [WO2017106607A1] | M-5049 | M5049
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This chemical structure (as the IUPAC name) was obtained from the special release of proposed INNs for COVID-related therapeutics that was published by the WHO in October 2020. The INN structure was identified as being identical to compound 73 from Merck's patent WO2017106607A1 (2017) in which it is claimed as a Toll-like receptor (TLR)7 and TLR8 antagonist for the treatment of immune disorders [3]. We speculated that this was Merck's clinical lead M5049, which is expected to prevent activation of TLR7/8 which detect single-stranded RNA from viruses including SARS-CoV-2 [1]. M5049 is administered orally. Name-to-structure was confirmed in spring 2021 [4]. The structure of M5049 was subsequently matched to the INN enpatoran.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 65.94
Molecular weight 320.12
XLogP 3.24
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#Cc1ccc(c2c1nccc2)N1C[C@H](N)C[C@@H](C1)C(F)(F)F
Isomeric SMILES N#Cc1ccc(c2c1nccc2)N1C[C@H](N)C[C@@H](C1)C(F)(F)F
InChI InChI=1S/C16H15F3N4/c17-16(18,19)11-6-12(21)9-23(8-11)14-4-3-10(7-20)15-13(14)2-1-5-22-15/h1-5,11-12H,6,8-9,21H2/t11-,12+/m0/s1
InChI Key BJXYHBKEQFQVES-NWDGAFQWSA-N
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
TLR7 Hs Antagonist Antagonist >6.0 pIC50 - 3
pIC50 >6.0 (IC50 <1x10-6 M) [3]
Description: Inhibition of activation of a TLR7/NFkB reporter in HEK293 cells (binned value).